Evidence in action: advancing care for angina with Shockwave Reducer

Sponsored by Shockwave Medical

Anchorperson: R. Al-Lamee

Spokesperson: T. Gori

Summary

Despite major advances in coronary revascularisation and medical therapy, angina continues to represent a significant clinical burden, affecting both quality of life and long-term patient management.

This EuroPCR 2026 session explores the emerging role of the Shockwave Reducer as a therapeutic option in patients with persistent angina. It highlights its unique mechanism of action and its potential relevance in both obstructive and non-obstructive coronary disease.

Current and emerging clinical evidence is reviewed, providing insight into outcomes across different patient populations and positioning this technology within the evolving angina treatment landscape.

Taken together, the data and mechanistic insights offer a broader perspective on how symptoms may be addressed beyond conventional revascularisation and medical therapy.

Learning Objectives

To understand the true prevalence and impact of angina
To gain an understanding of the Shockwave Reducer technology to treat patients with angina
To hear about the existing and future clinical data supporting the use of the Shockwave Reducer in obstructive and non-obstructive disease